These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis. Cao M; De Mel N; Jiao Y; Howard J; Parthemore C; Korman S; Thompson C; Wendeler M; Liu D MAbs; 2019; 11(6):1064-1076. PubMed ID: 31198090 [TBL] [Abstract][Full Text] [Related]
43. Mass spectrometric characterization of transglutaminase based site-specific antibody-drug conjugates. Farias SE; Strop P; Delaria K; Galindo Casas M; Dorywalska M; Shelton DL; Pons J; Rajpal A Bioconjug Chem; 2014 Feb; 25(2):240-50. PubMed ID: 24359082 [TBL] [Abstract][Full Text] [Related]
44. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates. Frigerio M; Kyle AF Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801 [TBL] [Abstract][Full Text] [Related]
45. Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues. Li X; Patterson JT; Sarkar M; Pedzisa L; Kodadek T; Roush WR; Rader C Bioconjug Chem; 2015 Nov; 26(11):2243-8. PubMed ID: 26161903 [TBL] [Abstract][Full Text] [Related]
46. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. McCombs JR; Owen SC AAPS J; 2015 Mar; 17(2):339-51. PubMed ID: 25604608 [TBL] [Abstract][Full Text] [Related]
48. An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates. Lansita JA; Burke JM; Apgar JF; Mounho-Zamora B Pharm Res; 2015 Nov; 32(11):3584-92. PubMed ID: 26108879 [TBL] [Abstract][Full Text] [Related]
49. Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry. Sang H; Lu G; Liu Y; Hu Q; Xing W; Cui D; Zhou F; Zhang J; Hao H; Wang G; Ye H Anal Chim Acta; 2017 Feb; 955():67-78. PubMed ID: 28088282 [TBL] [Abstract][Full Text] [Related]
50. Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides. Christie RJ; Fleming R; Bezabeh B; Woods R; Mao S; Harper J; Joseph A; Wang Q; Xu ZQ; Wu H; Gao C; Dimasi N J Control Release; 2015 Dec; 220(Pt B):660-70. PubMed ID: 26387744 [TBL] [Abstract][Full Text] [Related]
51. The impact of trisulfide modification of antibodies on the properties of antibody-drug conjugates manufactured using thiol chemistry. Liu R; Chen X; Dushime J; Bogalhas M; Lazar AC; Ryll T; Wang L MAbs; 2017 Apr; 9(3):490-497. PubMed ID: 28136017 [TBL] [Abstract][Full Text] [Related]
53. Alteration of Physicochemical Properties for Antibody-Drug Conjugates and Their Impact on Stability. Buecheler JW; Winzer M; Weber C; Gieseler H J Pharm Sci; 2020 Jan; 109(1):161-168. PubMed ID: 31408634 [TBL] [Abstract][Full Text] [Related]
54. Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. van Geel R; Wijdeven MA; Heesbeen R; Verkade JM; Wasiel AA; van Berkel SS; van Delft FL Bioconjug Chem; 2015 Nov; 26(11):2233-42. PubMed ID: 26061183 [TBL] [Abstract][Full Text] [Related]
55. Custom-Designed Affinity Capture LC-MS F(ab')2 Assay for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates. Su D; Ng C; Khosraviani M; Yu SF; Cosino E; Kaur S; Xu K Anal Chem; 2016 Dec; 88(23):11340-11346. PubMed ID: 27779866 [TBL] [Abstract][Full Text] [Related]
56. Characterization of Positional Isomers of Interchain Cysteine Linked Antibody-Drug Conjugates by High-Resolution Mass Spectrometry. Li K; Lin ZJ; Shi H; Ma Y Anal Chem; 2019 Jul; 91(13):8558-8563. PubMed ID: 31247726 [TBL] [Abstract][Full Text] [Related]
57. [Bioanalysis in the development of antibody-drug conjugates]. Li XL; Chen XY; Zhong DF Yao Xue Xue Bao; 2016 Apr; 51(4):517-28. PubMed ID: 29859519 [TBL] [Abstract][Full Text] [Related]
58. Localized conformational interrogation of antibody and antibody-drug conjugates by site-specific carboxyl group footprinting. Pan LY; Salas-Solano O; Valliere-Douglass JF MAbs; 2017; 9(2):307-318. PubMed ID: 27929747 [TBL] [Abstract][Full Text] [Related]
59. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates. Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591 [TBL] [Abstract][Full Text] [Related]
60. High-Throughput Platform to Identify Antibody Conjugation Sites from Antibody-Drug Conjugate Libraries. Yamazoe S; Hogan JM; West SM; Deng XA; Kotapati S; Shao X; Holder P; Lamba V; Huber M; Qiang C; Gangwar S; Rao C; Dollinger G; Rajpal A; Strop P Bioconjug Chem; 2020 Apr; 31(4):1199-1208. PubMed ID: 32178516 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]